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Abstract 21 
Glucocorticoid (GC) anti-inflammatory effects generally require a prolonged onset of action and 22 
involve genomic processes. Because of the rapidity of some of GC effects, however, the concept 23 
that non-genomic actions may contribute to GC mechanisms of action has arisen. While the 24 
mechanisms have not been completely elucidated, the non-genomic effects may play a role in the 25 
management of inflammatory diseases. For instance, we recently reported that GC “rapidly” 26 
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enhanced the effects of bronchodilators, agents used in the treatment of allergic asthma. In this 27 
review, we will discuss i) the non-genomic effects of GCs on pathways relevant to the pathogenesis 28 
of inflammatory diseases and ii) the putative role of membrane GC receptor. Since GC side effects 29 
are often considered to be generated through its genomic actions, understanding GC non-genomic 30 
effects will help design GCs with a better therapeutic index.  31 
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Mechanism of action of glucocorticoids (GC).  32 
GCs primarily mediate their effects by activating the ubiquitously expressed intracellular GC 33 
receptor (GR) (see Glossary) [1]. In its inactive state, the GR resides in the cytoplasm and, upon 34 
ligand activation, translocates to the cell nucleus to interact with GC response elements (GREs) 35 
thereby producing genomic effects that alter protein expression. Interestingly, evidence suggests 36 
that GCs also manifest almost immediate non-genomic actions on several signaling processes [2]. 37 
GC non-genomic effects involve non-specific interactions with the cell membrane, or specific 38 
interactions with cytosolic GRs (cGR) or membrane-bound GRs (mGR) (Table 1). This report 39 
summarizes the current knowledge on non-genomic effects of GCs, with a focus on GR-mediated 40 
events and GR-associated signaling pathways. Where appropriate, potential links to inflammatory 41 
diseases will be highlighted in the main text and their potential impact will be discussed in Box 1 42 
and 2. 43 
 44 
GCs exert rapid effects on levels of intracellular calcium.  45 
Studies suggest that GC rapidly (within seconds) modulates basal intracellular calcium levels 46 
and agonist-induced calcium mobilization (Tables 2 & 3). 47 
Effects of GCs on intracellular calcium homeostasis. GCs can increase or decrease cytosolic 48 
calcium depending on the cell type. Evidence from non-immune cells, such as primary or 49 
immortalized human bronchial epithelial cells, consistently demonstrate that acute exposure to 50 
GC, and to a lesser extent to the mineralocorticoid (MC), aldosterone, reduces basal [Ca2+]i [3, 4]. 51 
Similarly, in rat thymocytes [5] and mouse neuroblastoma cells [6] [Ca2+]i decreased following 52 
acute exposure to GC, and in cichlid fish pituitary cells cortisol inhibited [Ca2+]i and reduced 53 
prolactin secretion [7]. However, in immune cells, it is unclear if GCs genuinely exert non-54 
genomic effects on basal [Ca2+]i. For example, while acute exposure to GC was reported to 55 
decrease [Ca2+]i in leukocytes, these leukocytes were obtained from donors who were treated with 56 
oral prednisolone for 7 days [8], potentially confounding the results of the study. Similarly, studies 57 
in human lymphoblasts show that cortisol markedly reduced basal [Ca2+]i only after 48 hrs of 58 
treatment [9]. These data argue against a role for non-genomic effects of GC in altering basal 59 
[Ca2+]i in immune cells. 60 
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With regard to the lungs, evidence supports that a variety of GCs differentially modulate basal 61 
[Ca2+]i upon immediate exposure. For instance, the acute inhibitory effects of dexamethasone 62 
(within 30 seconds) on basal [Ca2+]i in bronchial epithelial cells were comparable to triamcinolone 63 
acetonide and hydrocortisone but not to budesonide [10]. Interestingly, the GR antagonist RU486 64 
and the protein synthesis inhibitor cycloheximide failed to prevent these acute GC effects, 65 
suggesting the involvement of GR-independent and non-genomic pathways. These observed 66 
effects could be due to the various degrees of lipophilicity among GCs, as well as direct 67 
interactions of GCs with the cell membrane [10]. Non-genomic mechanisms have been proposed 68 
mostly based on the use of pharmacological inhibitors. Urbach and colleagues found that the rapid 69 
GC effects involved pathways regulated by the SERCA type Ca2+-ATPase pump, adenylyl cyclase 70 
and protein kinase A (PKA) but not protein kinase C (PKC) [10]. Collectively, these studies show 71 
the complexity of mechanisms involved in the rapid, GR-independent effect of GCs on [Ca2+]i, 72 
which likely occurs through an adenylyl cyclase/PKA mediated stimulation of a thapsigargin 73 
sensitive Ca2+-ATPase [10].  74 
Conversely, acute stimulatory effects of GC on basal calcium levels have been documented. A 75 
brief exposure to GC can increase [Ca2+]i in several cell types. For example, in mouse cortical 76 
collecting duct cells, dexamethasone and aldosterone increased [Ca2+]i. Interestingly, the effect of 77 
aldosterone was mediated by a non-genomic activation of PKC pathway as evidenced by the 78 
abolishment of its effect on basal [Ca2+]i in the presence of the PKC inhibitor, chelerythrine 79 
chloride, but not the mRNA synthesis inhibitor, actinomycin D [11]. Similarly, in rat vascular 80 
smooth muscle cells, GCs rapidly increased [Ca2+]i [12] potentially through GC-mediated 81 
increases in inositol 1,4,5-triphosphate (IP3) levels associated with the translocation of the 82 
calcium- and lipid-dependent PKC from the cytosolic to the membranous compartment [13]. In 83 
these cells, while the administration of epinephrine by itself had little effect on IP3 levels, 84 
epinephrine potentiated the rapid response induced by cortisol [13]. Collectively, these findings 85 
highlight a role of PKC in the rapid increase of basal [Ca2+]i by GCs. 86 
 87 
Effects of GCs on agonist-induced calcium mobilization. The effects of GCs on agonist-88 
induced calcium mobilization are variable depending on the agonist, the extra-cellular stimuli and 89 
the cell type. Evidence suggests that GCs rapidly inhibit, at least partially, the ability of adenosine 90 
triphosphate (ATP) to increase [Ca2+]i in some cell types. In human bronchial epithelial cells for 91 
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example, 15 min exposure to dexamethasone (1 nM) markedly reduced ATP-induced increases in 92 
[Ca2+]i. The ATP-induced Ca2+ response was independent of extracellular calcium but did involve 93 
a Ca2+-mobilization from thapsigargin-sensitive intracellular stores [10]. Similarly, in murine HT4 94 
neuroblastoma cells, acute (5 min) pre-incubation with corticosterone dose-dependently inhibited 95 
[Ca2+]i signals induced by ATP [6]. Unlike in human bronchial epithelial cells, the Ca2+-response 96 
induced by ATP in these cells relies on Ca2+-influx across the plasma membrane and Ca2+-release 97 
from intracellular stores [6]. Inhibition of PKA abrogated the inhibitory action of corticosterone 98 
on ATP-induced Ca2+-elevation, whereas little influence was observed with respect to PKC 99 
inhibition. Additional studies demonstrated that these GC inhibitory effects were unaffected by 100 
GR blockade. These key findings obtained from studies in HT4 cells suggest that GC activates 101 
membrane-initiated, non-genomic, PKA-dependent, PKC-independent pathways [6, 14]. In 102 
contrast, in rat B103 neuroblastoma cells, the inhibitory effects of corticosterone on serotonin-103 
induced peak [Ca2+]i were found to be PKC-dependent [15]. Together, these studies suggest that 104 
the mechanisms mediating the acute non-genomic effects of GC on agonist-evoked calcium 105 
mobilization are stimuli and cell type-dependent.  106 
In contrast to human bronchial epithelial and murine HT4 neuroblastoma cells, 107 
pretreatment of guinea pig cochlear spiral ganglion neurons (SGN) with dexamethasone (10 min) 108 
enhanced ATP-induced Ca2+-mobilization [16]. This effect was prevented in the presence of a GR 109 
antagonist and mediated by rapid Ca2+-influx through activation of ionotropic purinergic P2X 110 
receptors [16]. Of note, all P2X subtypes are expressed in SGN albeit to different extents [17, 18]. 111 
Similarly, in rat hippocampal neurons, pretreatment with corticosterone or dexamethasone for 10-112 
20 min prolonged N-methyl-D-aspartate (NMDA)-induced transient elevation in [Ca2+]i [19]. 113 
Importantly, the steroid effect was reversed by the removal of corticosterone indicating that the 114 
steroid effect was not due to irreversible impairment of Ca2+-extrusion from the neurons. 115 
Thapsigargin and cyclohexamide had little effect on the potentiating effect of corticosterone, 116 
excluding the involvement of a thapsigargin sensitive Ca2+-ATPase or de novo protein synthesis, 117 
respectively. Interestingly, the GC effect was reproduced by the use of a membrane impermeable 118 
BSA-conjugated cortisol, suggesting that mGR likely underlies the rapid non-genomic effects of 119 
GC [19]. However, canonical genomic actions of GC can also alter Ca2+ mobilization. In human 120 
lymphoblasts, while cortisol reduced basal [Ca2+]i (as indicated above), Ca2+-mobilization induced 121 
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by platelet activating factor (PAF) is enhanced only by chronic treatment (48 hrs) with cortisol [9] 122 
(Figure 1). 123 
 124 
GCs rapidly modulate skeletal and smooth muscle function.   125 
Several studies have reported variable acute effects of GCs on muscle reactivity and tone. 126 
The specific example of airway smooth muscle cells in the pathogenesis of inflammatory diseases 127 
is highlighted in Box 1. In mouse skeletal myotubes (C2C12 immortalized myoblasts), treatment 128 
with dexamethasone (for less than 20 min) reduced glucose uptake induced by electrical pulse 129 
stimulation (EPS)-mediated contraction, in a Ca2+/calmodulin protein kinase II (CaMKII) and 130 
AMP activated protein kinase (AMPK) dependent fashion [20]. The effects were unaffected by 131 
blockade of GR (RU486) or inhibition of protein synthesis (cyclohexamide), indicating a rapid 132 
non-genomic and GR-independent effect. In another study, cortisol synergized with isoprenaline 133 
in reducing tracheal spasms in response to histamine [21]. The spasmolytic effect was fully 134 
prevented in the presence of RU486 (implicating a GR-dependent pathway), partially reduced by 135 
PKC inhibition, but was unaffected by actinomycin D (excluding de novo RNA synthesis) again 136 
suggesting a non-genomic, GR-mediated signaling pathway involving PKC [21].  137 
Other studies support a role for GCs in rapidly reducing airway smooth muscle (ASM) 138 
tone. Pretreatment with budesonide (within 15 min) suppressed histamine-induced isometric 139 
tension in guinea pig tracheal rings and shrinkage in individual tracheal ASM cells; effects that 140 
were unaffected by cycloheximide (suggesting non-genomic actions by budesonide) [22]. Unlike 141 
the findings by Wang and colleagues [21], these budesonide effects were insensitive to RU486, 142 
excluding classic GR involvement [22]. Similarly, in murine ASM cells, exposure to 143 
dexamethasone for 10 min decreased basal [Ca2+]i and reduced peak elevations in [Ca2+]i induced 144 
by acetylcholine, effects that were insensitive to GR blockade and cycloheximide [23]. 145 
Consistently, studies using an in vivo guinea pig model of asthma, an established model to study 146 
allergen-induced asthmatic reactions and airway hyperresponsiveness [24], revealed a beneficial 147 
effect on ovalbumin-induced changes in lung resistance and compliance by acutely inhaled 148 
budesonide. The protective effects of budesonide were evident within 10 minutes, suggesting a 149 
non-genomic course of action [25]. In summary, GCs have acute spasmolytic actions in ASM that 150 
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can require both GR-dependent and -independent pathways, and potentially PKC-mediated 151 
signaling. 152 
A recent study in rat vascular smooth muscle cells under conditions of lipopolysaccharide 153 
(LPS)-induced septic shock showed that dexamethasone treatment for 10 min promotes 154 
norepinephrine (NE)-induced phosphorylation of key proteins associated with contraction [26]. 155 
While no significant effect on myosin light chain 20 (MLC20) phosphorylation was observed after 156 
exposure to either dexamethasone or NE alone, the combined treatment markedly enhanced 157 
phospho-MLC20, an effect that was unaltered by GR blockade with RU486. Interestingly, 158 
inhibition of Rho-kinase with Y-27632 completely reversed the potentiating effects of 159 
dexamethasone on NE-induced phospho-MLC20. Together, these findings could be of clinical 160 
significance and indicate that the impaired vascular response to NE observed in septic shock may 161 
be restored by short-term exposure to dexamethasone through non-genomic activation of Rho-162 
kinase activity [26].   163 
 164 
GCs exert rapid effects on Reactive Oxygen Species (ROS)/Reactive Nitrogen Species 165 
(RNS).  166 
Studies demonstrated a rapid effect of GCs on ROS generation and the involvement of 167 
nitric oxide (NO) in mediating some GC effects. An example of the role NO/ROS in the 168 
pathogenesis of inflammatory disease is highlighted in Box 2. In breast cancer cells, cortisol 169 
rapidly increased levels of ROS and RNS (as early as 15 min) and induced DNA damage. The GR 170 
antagonist (RU486) blocked the cortisol effect while L-NAME and 1400 W dihydrochloride 171 
demonstrated the involvement of nitric oxide synthase (NOS) and inducible (i)NOS, respectively. 172 
The pharmacological inhibition of Src by PP2 prevented GC-induced RNS elevation, suggesting 173 
the ability of GC to rapidly stimulate Src- and iNOS-dependent release of damaging RNS levels 174 
[27].  175 
Rapid effects of GCs on endothelial NOS (eNOS), an important mediator of vascular 176 
integrity with anti-inflammatory, anti-ischemic, and anti-atherogenic properties, have been 177 
described as well [28-30]. Indeed, the treatment of human vascular endothelial cells with 178 
dexamethasone rapidly enhanced (as early as 10 min), in a concentration-dependent manner, eNOS 179 
activity, NO-production and NO-dependent vasorelaxation [31]. These GC effects were abrogated 180 
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by RU486, PI3-kinase inhibitors wortmannin and LY292002, or L-NAME, but not by the 181 
transcriptional inhibitor actinomycin D.  182 
Additional evidence supporting rapid effects of GCs on NOS/NO showed an augmented 183 
ATP-induced, NOS-dependent NO release in guinea pig type I spiral ganglion neurons by 184 
dexamethasone that was thought to be a consequence of ATP-induced [Ca2+]i [16]. Similarly, GR-185 
mediated increases in [Ca2+]i, eNOS phosphorylation, and NO production, were observed in 186 
human umbilical vein endothelial cells [32]. Interestingly, NO production increased [Ca2+]i 187 
originating from intracellular and extracellular Ca2+ sources [32]. 188 
The PI3K/Akt pathway is critical in the activation of NO signaling, e.g. phosphorylation 189 
of eNOS [33], and the involvement of this pathway in the rapid effects of GCs has been 190 
documented [33]. For example, dexamethasone rapidly increased (within 20 min), in a dose-191 
dependent manner, GR-dependent phosphorylation and activation of PI3K as demonstrated by 192 
phosphorylation of Akt and glycogen synthase kinase (GSK)-3, indicating that GCs can 193 
functionally activate PI3K and downstream targets in human endothelial cells [31]. The potential 194 
clinical relevance of these observations was confirmed in two different mouse models of ischemic 195 
injury (i.e. transient myocardial ischemia and transient focal cerebral ischemia) where GC exerted 196 
rapid protective effects (within 30 min) via GR-dependent activation of PI3K and eNOS pathways 197 
as evidenced by the administration of RU486, wortmannin and L-NAME, respectively [31, 32]. 198 
Additional studies in COS-7 cells demonstrated a key role for GR in GC-induced activation of the 199 
PI3K/Akt pathway. When cells were transfected with a dimerization-defective GR mutant (A458T, 200 
a construct that is unable to bind DNA and transactivate GC target genes), acute dexamethasone 201 
stimulation still activated the PI3K/Akt pathway [34]. Together, these findings suggest the 202 
involvement of a non-transcriptional/non-genomic mechanism in the GR-dependent activation of 203 
PI3K/Akt by GCs.  204 
Since NO signaling plays a key role in chronic airway inflammatory diseases, such as 205 
asthma and COPD [35], we believe that the cross-talk between GC and NO signaling warrants 206 
further investigation to determine whether the rapid effects of GC on NO signaling would be 207 
beneficial or detrimental in disease pathogenesis. 208 
 209 
GCs exert acute effects on inflammatory and apoptotic pathways. 210 
9 
 
Evidence shows rapid non-transcriptional actions of GCs on inflammation both in 211 
transformed cells and immune cells. In transformed cells, such as A549 adenocarcinoma cells, 212 
acute exposure (as early as 1 min) to dexamethasone rapidly inhibited epidermal growth factor 213 
(EGF)-induced arachidonic acid (AA) release, an important mediator of inflammation [36]. This 214 
inhibitory effect was due to hindering the recruitment of Grb2, p21ras and Raf to the EGF receptor 215 
(EGFR) through a GR-dependent (RU486-sensitive) and transcription-independent (actinomycin 216 
D-insensitive) mechanism. The inhibition of Grb2 recruitment was accompanied by lipocortin-1 217 
recruitment to EGFR in the cell membrane. Subsequently, lipocortin-1 competitively inhibited 218 
Grb2 binding to EGFR, thereby blocking the recruitment of critical signaling molecules necessary 219 
for EGF actions [36].  220 
The acute effects of GCs on inflammatory pathways were also observed in immune cells, 221 
such as human neutrophils, where acute exposure (5 min) to methylprednisolone or hydrocortisone 222 
significantly inhibited N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced neutrophil 223 
degranulation, effects that were not prevented by RU486 or cycloheximide treatments, suggesting 224 
the involvement of GR-independent and non-genomic pathways [37]. Also, in murine 225 
macrophages acutely treated with dexamethasone (30 min), toll like receptor 9 (TLR9)-induced 226 
activation of different inflammatory signaling pathways, such as those involving NF-κB and 227 
mitogen-activated protein kinases (MAPKs), was dramatically suppressed [38]. Following TLR-9 228 
engagement, IL-1R-associated kinase 1 (IRAK1) is recruited to the cell membrane. A critical step 229 
in activating the TLR signaling cascade is the ubiquitination of IRAK1 through its physical 230 
interaction with the E3 ligase, β-TrCP. Such ubiquitination and degradation of IRAK1 promotes 231 
the trafficking of the “TNFR-associated factor 6 (TRAF6)– TAK1 adaptor proteins (TAB)– 232 
Transforming growth factor beta-activated kinase 1 (TAK1)” complex to the cytosol to 233 
subsequently induce MAPK and NF-κB activation. Dexamethasone inhibition of IRAK1 234 
ubiquitination did not occur in the presence of RU486 suggesting the involvement of GR-235 
dependent mechanisms [38]. Further investigation of the molecular mechanisms revealed that by 236 
physically interacting with IRAK1, GR interferes with the interaction between β-TrCP and IRAK1 237 
thereby impeding its ubiquitination, a critical step in the activation of the TLR9-dependent 238 
inflammatory cascade [38]. 239 
Rapid GC treatment can also exert pro-inflammatory action in other cell types. For 240 
example, in PC12 cells (cell line derived from rat adrenal gland), corticosterone induced rapid 241 
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activation (within 15 min) of ERK1/2, p38, and JNK in a PKC-dependent manner [39, 40]. The 242 
activation of MAPK pathways following GC treatment appears to be mediated by the putative 243 
mGR, since corticosterone-BSA can rapidly (with 15 min) activate all MAPKs [39, 40]. Similarly, 244 
in rat vascular smooth muscle cells, dexamethasone either alone or in combination with NE, 245 
rapidly (within 10 min) induces ERK1/2 and p38 MAPK activities [26]. Thus, in certain cells, GCs 246 
can activate MAPK in a non-genomic manner. 247 
In CCRF-CEM cells, cell line derived from human T-cells (from pediatric ALL patients), 248 
sensitivity to acute dexamethasone induced cell death was determined in the presence and absence 249 
of phosphodiesterase (PDE) inhibitors [41]. Non-specific PDE and specific PDE4 inhibition 250 
reversed steroid resistance and markedly increased sensitivity to dexamethasone. This effect is 251 
likely due to increased cAMP levels, consistent with abundant documentation on interactions 252 
between GR and cAMP pathways in the induction of apoptosis in lymphoid cells by both [42, 43]. 253 
To date, the mechanisms of cAMP-induced apoptosis are unclear, but the presence of GR appears 254 
to be required, even in the absence of GCs. For instance, in parental T-cells, elevation of cAMP, 255 
with either forskolin or dibutyryl cAMP, induced apoptotic cells death, whereas GR deficient cells 256 
were insensitive to the apoptotic effects of cAMP elevation. When GR expression was 257 
reconstituted by transfection, not only was GC sensitivity restored, but the sensitivity to cytolytic 258 
effects induced by cAMP was promoted as well [42].  259 
 The effects of GCs on the mitochondrial control of cell metabolism and apoptosis have 260 
been extensively reviewed elsewhere [44-47]. For instance, Sekeris and colleagues were the first 261 
to discover the presence of GR in mitochondria [48]. Through its acute non-genomic effects, GCs 262 
promote mitochondrial apoptotic pathways resulting in the disruption of the mitochondrial 263 
membrane-potential and the release of pro-apoptotic factors such as Cytochrome C [49]. 264 
Importantly, the translocation of GR from the cytoplasm to the mitochondria correlates with the 265 
sensitivity of a given cell type to GC-induced apoptosis [50, 51]. In line with this, recent studies 266 
in mouse thymocytes showed that short term treatment with GC induces a direct interaction of GR 267 
with the pro-apoptotic Bcl2 family member associated proteins such as Bim [52]. Such interaction 268 
subsequently activates Bax decreasing thereby the mitochondrial membrane potential, 269 
Cytochrome C release, and Caspase-9 activation. However, it important to note that the effects of 270 
GC on the mitochondria control of apoptosis involve also genomic pathways.  For example, in 271 
murine neuronal stem cells, dexamethasone was able to augment 2,3-methoxy-1,4-272 
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naphthoquinone-induced apoptosis where a large percentage of studied genes involved in the 273 
mitochondrial respiratory chain and some encoding for anti-oxidant enzymes were downregulated 274 
by long-term treatment with GC [53]. These events allowed GCs to increase cellular sensitivity to 275 
oxidative stress promoting thereby neurotoxicity. This is clinically relevant as it can occur during 276 
prenatal exposure of the fetal brain to excess GCs [53].  277 
Potential role of a putative mGR in mediating the rapid effects of GCs.  278 
As previously described, the rapid non-genomic effects can, at least in part, be mediated 279 
through a putative mGR. Over the years, caveolin-1 (Cav-1), the major protein component of 280 
caveolae, has been implicated as a scaffold for the organization of several cytoplasmic signal 281 
complexes at the plasma membrane [54, 55]. In lung epithelial cells (A549), dexamethasone 282 
treatment leads to a rapid (within 2 min) phosphorylation of Cav-1 and protein kinase B (PKB)/Akt 283 
in a Src-dependent fashion [56]. Subcellular fractionation revealed co-localization of GR and Src 284 
to caveolin-containing membrane fractions [56]. Interfering with caveolae/caveolin (by disruption 285 
of lipid raft formation, impairment of function using dominant negative caveolin, down regulation 286 
of Cav-1 using shRNA, or genetic ablation of Cav-1) prevented acute (within 2 min) GC-induced 287 
PKB phosphorylation. Of note, caveolin down-regulation had little effect on GC-mediated 288 
transactivation, supporting the existence of a putative mGR. Further functional studies in caveolin 289 
knockout cells revealed considerable inhibition of GC-mediated cell growth arrest, suggesting that 290 
membrane-proximal signals acutely initiated by GC are required to mediate delayed effects (anti-291 
proliferative effects) previously ascribed exclusively to the nuclear actions of GR [56]. Further 292 
evidence supporting a role for caveolae in mGR function stems from studies of membrane nuclear 293 
receptors such as estrogen receptor (ER) [57] showing requirement of Cav-1 in mediating acute 294 
cellular actions. Indeed, using epitope proximity ligation assays, Watson and colleagues 295 
demonstrated interactions of ERα with Cav-1. Interestingly, the use of nystatin, which binds to 296 
cholesterol and disrupts caveolar structures, blocked estrogen-induced rapid (5 min) ERK 297 
activation in pituitary tumor cells [57]. Together these findings indicate a critical role of Cav-1 in 298 
acute nuclear receptor/steroid signaling.  299 
While the expression of mGR has been demonstrated in a myriad of cell types [58], the co-300 
localization and cross-talk between mGR and Cav-1 is variable and highly cell-specific. Indeed, 301 
in U2-OS and MCF-7 cells, double recognition proximity ligation assays demonstrated the 302 
physical association of Cav-1 with the mGR [58]. However, studies in human CD14+ monocytes 303 
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showed that mGR and Cav-1 are not co-localized and overexpression of the recombinant Cav‐1 304 
transcript in human K562 chronic myelogenous leukemia cells did not affect mGR 305 
expression/appearance suggesting that in these specific cell lines Cav‐1 is not the limiting factor 306 
for mGR expression/appearance, without ruling out the possibility that it is a component of the 307 
transport machinery of GR from the cytosol to the membrane [59]. Palmitoylation, a critical post-308 
translational modification occurring through the addition of fatty acid (e.g. palmitic acid) on amino 309 
acid residues of membrane proteins, plays a major role in the subcellular trafficking of proteins 310 
between membrane compartments [60].  Interestingly, the involvement of palmitoylation in the 311 
recruitment of other nuclear receptors, such as ER, to the plasma membrane has been reported 312 
[61]. Recent studies investigated whether this process is necessary for the recruitment of GR to the 313 
membrane and its co-localization with Cav-1 in COS-7 cells. Treatment of cells with the 314 
palmitoylation inhibitor, 2-bromopalmitate, had little effect on membrane localization of GR and 315 
its co-localization with Cav-1, and little influence on the acute effects of GC on MAPK signaling 316 
pathways. In addition, human GRα did not undergo S-palmitoylation, rendering this process 317 
unlikely to modulate membrane recruitment of GR [62]. Future studies on the mechanisms 318 
underlying GR recruitment to caveolae rich parts and its potential association with Cav-1 are 319 
warranted, specifically in airway cells.  320 
Several studies have reported an interaction of mGR with other membrane receptors, 321 
particularly GPCRs [63]. Zhang and colleagues demonstrated the involvement of mGR and GPCR-322 
dependent mechanisms in the rapid effect (as early as 1 min) of corticosterone on NMDA-evoked 323 
currents in hippocampal neurons [63] and further suggested that mGR may couple to multiple G 324 
proteins, including Gs and Gq/11. Other studies indicate that mGR directly elicits the activation of 325 
downstream intracellular signaling pathways. For instance, corticosterone might act via mGR to 326 
rapidly elicit PKC-dependent activation of ERK1/2 MAPK pathway (with 15 min) in PC12 cells 327 
[39]. Interestingly, proteomic analysis of the lymphoma cell line CCRF-CEM identified 128 328 
proteins that were differentially regulated by the specific activation of mGR using BSA-conjugated 329 
cortisol for a short-term period (5 and 15 min)  [58]. These actions were unique to mGR, as no 330 
activation of cGR target genes, such as GILZ, were observed. The majority of networks rapidly 331 
activated by mGR were mainly involved in cellular growth and cancer (after 5 min treatment with 332 
cortisol-BSA), cellular development, or hematological system development and function (after 15 333 
min treatment with cortisol-BSA). Ingenuity pathway analysis provided strong evidence that mGR 334 
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is involved in pro-apoptotic, immune-modulatory, and metabolic pathways that are also regulated 335 
by GCs through cGR, suggesting that acute mGR stimulation can trigger rapid early priming 336 
events, ultimately paving the way for the slower genomic activities by GCs [58].  337 
 338 
Concluding Remarks and Future Perspectives.  339 
Although we have some insight in how GCs regulate different signaling pathways in a non-340 
genomic fashion, future in depth investigations are warranted to further unravel details of these 341 
complex interactions. Indeed, key questions (see Outstanding Questions) still need careful 342 
consideration and additional research must address several important issues: i) the differential 343 
nature of non-genomic effects of GC in immune cells versus non-immune/structural cells; ii) 344 
differences between non-genomic effects of various steroids based on their lipophilicity [10]; iii) 345 
the fact that not all non-genomic effects are GR-mediated (RU486 insensitive) and may be due to 346 
non-specific interactions of GC with the cell membrane [2]; iv) the possibility that non-genomic 347 
and genomic effects are interconnected, where the acute non-genomic effects pave the way for the 348 
slower genomic activities of GCs [58]; and v) the significant role of Cav-1, and possibly other 349 
scaffolding/anchoring proteins, as a modulator of mGR activation, where the relative numbers of 350 
mGR associated with Cav-1 are critical in mediating non-genomic effects of GC [58, 64, 65]. Since 351 
side effects associated with GC therapy are often generated through its genomic actions [66], 352 
uncovering the non-genomic actions of GC with beneficial effects will likely lead to the 353 
development of compounds that selectively activate non-genomic signaling and thus have 354 
improved therapeutic profiles.  355 
 356 
Acknowledgement. This work was funded by following grant from National Institute of Health 357 
(NIH): 7R01HL111541-07 (OT), HL 2P01HL114471-06 (RP) and GM107094 (RO). 358 
  359 
14 
 
References. 360 
1. Lemanske, R.F., Jr. and Busse, W.W. (2003) 6. Asthma. J Allergy Clin Immunol. 111, S502-361 
19. 362 
2. Song, I.H. and Buttgereit, F. (2006) Non-genomic glucocorticoid effects to provide the basis for 363 
new drug developments. Mol Cell Endocrinol. 246, 142-6. 364 
3. Urbach, V. and Harvey, B.J. (2001) Rapid and non-genomic reduction of intracellular [Ca(2+)] 365 
induced by aldosterone in human bronchial epithelium. J Physiol. 537, 267-75. 366 
4. Urbach, V. et al. (2006) Rapid anti-secretory effects of glucocorticoids in human airway 367 
epithelium. Steroids. 71, 323-8. 368 
5. Buttgereit, F. et al. (1997) Methylprednisolone inhibits uptake of Ca2+ and Na+ ions into 369 
concanavalin A-stimulated thymocytes. Biochem J. 326 ( Pt 2), 329-32. 370 
6. Han, J.Z. et al. (2005) Inhibition of ATP-induced calcium influx in HT4 cells by glucocorticoids: 371 
involvement of protein kinase A. Acta Pharmacol Sin. 26, 199-204. 372 
7. Borski, R.J. et al. (1991) Cortisol rapidly reduces prolactin release and cAMP and 45Ca2+ 373 
accumulation in the cichlid fish pituitary in vitro. Proc Natl Acad Sci U S A. 88, 2758-62. 374 
8. Chhabra, S.K. et al. (1999) Decreased sodium-potassium and calcium adenosine triphosphatase 375 
activity in asthma: modulation by inhaled and oral corticosteroids. Indian J Chest Dis Allied Sci. 376 
41, 15-26. 377 
9. Gardner, J.P. and Zhang, L. (1999) Glucocorticoid modulation of Ca2+ homeostasis in human 378 
B lymphoblasts. J Physiol. 514 ( Pt 2), 385-96. 379 
10. Urbach, V. et al. (2002) Rapid non-genomic inhibition of ATP-induced Cl- secretion by 380 
dexamethasone in human bronchial epithelium. J Physiol. 545, 869-78. 381 
11. Harvey, B.J. and Higgins, M. (2000) Nongenomic effects of aldosterone on Ca2+ in M-1 382 
cortical collecting duct cells. Kidney Int. 57, 1395-403. 383 
12. Wehling, M. et al. (1995) Nongenomic effects of aldosterone on intracellular Ca2+ in vascular 384 
smooth muscle cells. Circ Res. 76, 973-9. 385 
13. Steiner, A. et al. (1988) Stimulation of the phosphoinositide signalling system as a possible 386 
mechanism for glucocorticoid action in blood pressure control. J Hypertens Suppl. 6, S366-8. 387 
14. Han, J.Z. et al. (2002) Evoked intracellular Ca2+ elevations in HT4 neuroblastoma cells. 388 
Neuroreport. 13, 1089-94. 389 
15 
 
15. Han, J.Z. et al. (2002) A rapid, nongenomic action of glucocorticoids in rat B103 390 
neuroblastoma cells. Biochim Biophys Acta. 1591, 21-7. 391 
16. Yukawa, H. et al. (2005) Acute effects of glucocorticoids on ATP-induced Ca2+ mobilization 392 
and nitric oxide production in cochlear spiral ganglion neurons. Neuroscience. 130, 485-96. 393 
17. Brandle, U. et al. (1999) Gene expression of P2X-receptors in the developing inner ear of the 394 
rat. Neurosci Lett. 273, 105-8. 395 
18. Xiang, Z. et al. (1999) P2X receptor immunoreactivity in the rat cochlea, vestibular ganglion 396 
and cochlear nucleus. Hear Res. 128, 190-6. 397 
19. Takahashi, T. et al. (2002) Corticosterone acutely prolonged N-methyl-d-aspartate receptor-398 
mediated Ca2+ elevation in cultured rat hippocampal neurons. J Neurochem. 83, 1441-51. 399 
20. Gong, H. et al. (2016) Dexamethasone rapidly inhibits glucose uptake via non-genomic 400 
mechanisms in contracting myotubes. Arch Biochem Biophys. 603, 102-9. 401 
21. Wang, C. et al. (2012) Glucocorticoid decreases airway tone via a nongenomic pathway. Respir 402 
Physiol Neurobiol. 183, 10-4. 403 
22. Sun, H.W. et al. (2006) Rapid inhibitory effect of glucocorticoids on airway smooth muscle 404 
contractions in guinea pigs. Steroids. 71, 154-9. 405 
23. Sun, H.W. et al. (2010) [Rapid inhibitory effect of glucocorticoids on peak of [Ca2+]i and PLC 406 
in airway smooth muscle]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 26, 440-3. 407 
24. Meurs, H. et al. (2006) A guinea pig model of acute and chronic asthma using permanently 408 
instrumented and unrestrained animals. Nat Protoc. 1, 840-7. 409 
25. Zhou, J. et al. (2003) Rapid nongenomic effects of glucocorticoids on allergic asthma reaction 410 
in the guinea pig. J Endocrinol. 177, R1-4. 411 
26. Zhang, T. et al. (2013) Dexamethasone induces rapid promotion of norepinephrinemediated 412 
vascular smooth muscle cell contraction. Mol Med Rep. 7, 549-54. 413 
27. Flaherty, R.L. et al. (2017) Glucocorticoids induce production of reactive oxygen 414 
species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast 415 
cancer. Breast Cancer Res. 19, 35. 416 
28. Ishida, A. et al. (1997) Induction of the cyclin-dependent kinase inhibitor 417 
p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. J 418 
Biol Chem. 272, 10050-7. 419 
16 
 
29. Limbourg, F.P. and Liao, J.K. (2003) Nontranscriptional actions of the glucocorticoid receptor. 420 
J Mol Med (Berl). 81, 168-74. 421 
30. Loscalzo, J. (1995) Nitric oxide and vascular disease. N Engl J Med. 333, 251-3. 422 
31. Hafezi-Moghadam, A. et al. (2002) Acute cardiovascular protective effects of corticosteroids 423 
are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 8, 424 
473-9. 425 
32. Leung, K.W. et al. (2009) Protopanaxadiol and protopanaxatriol bind to glucocorticoid and 426 
oestrogen receptors in endothelial cells. Br J Pharmacol. 156, 626-37. 427 
33. Dimmeler, S. et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-428 
dependent phosphorylation. Nature. 399, 601-5. 429 
34. Limbourg, F.P. et al. (2002) Rapid nontranscriptional activation of endothelial nitric oxide 430 
synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin 431 
Invest. 110, 1729-38. 432 
35. Meurs, H. et al. (2003) Arginase and asthma: novel insights into nitric oxide homeostasis and 433 
airway hyperresponsiveness. Trends Pharmacol Sci. 24, 450-5. 434 
36. Croxtall, J.D. et al. (2000) Glucocorticoids act within minutes to inhibit recruitment of 435 
signalling factors to activated EGF receptors through a receptor-dependent, transcription-436 
independent mechanism. Br J Pharmacol. 130, 289-98. 437 
37. Liu, L. et al. (2005) Rapid non-genomic inhibitory effects of glucocorticoids on human 438 
neutrophil degranulation. Inflamm Res. 54, 37-41. 439 
38. Kong, F. et al. (2017) Inhibition of IRAK1 Ubiquitination Determines Glucocorticoid 440 
Sensitivity for TLR9-Induced Inflammation in Macrophages. J Immunol. 199, 3654-3667. 441 
39. Qiu, J. et al. (2001) Rapid activation of ERK1/2 mitogen-activated protein kinase by 442 
corticosterone in PC12 cells. Biochem Biophys Res Commun. 287, 1017-24. 443 
40. Li, X. et al. (2001) Corticosterone-induced rapid phosphorylation of p38 and JNK mitogen-444 
activated protein kinases in PC12 cells. FEBS Lett. 492, 210-4. 445 
41. Ogawa, R. et al. (2002) Inhibition of PDE4 phosphodiesterase activity induces growth 446 
suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human 447 
acute lymphoblastic leukemia cells. Blood. 99, 3390-7. 448 
42. Kiefer, J. et al. (1995) Functional glucocorticoid receptor expression is required for cAMP-449 
mediated apoptosis in a human leukemic T cell line. J Immunol. 155, 4525-8. 450 
17 
 
43. McConkey, D.J. et al. (1993) Cyclic AMP potentiates glucocorticoid-induced endogenous 451 
endonuclease activation in thymocytes. FASEB J. 7, 580-5. 452 
44. Gavrilova-Jordan, L.P. and Price, T.M. (2007) Actions of steroids in mitochondria. Semin 453 
Reprod Med. 25, 154-64. 454 
45. Psarra, A.M. et al. (2009) Interaction of mitochondrial thioredoxin with glucocorticoid receptor 455 
and NF-kappaB modulates glucocorticoid receptor and NF-kappaB signalling in HEK-293 cells. 456 
Biochem J. 422, 521-31. 457 
46. Psarra, A.M. and Sekeris, C.E. (2009) Glucocorticoid receptors and other nuclear transcription 458 
factors in mitochondria and possible functions. Biochim Biophys Acta. 1787, 431-6. 459 
47. Psarra, A.M. et al. (2006) The mitochondrion as a primary site of action of steroid and thyroid 460 
hormones: presence and action of steroid and thyroid hormone receptors in mitochondria of animal 461 
cells. Mol Cell Endocrinol. 246, 21-33. 462 
48. Demonacos, C. et al. (1993) Import of the glucocorticoid receptor into rat liver mitochondria 463 
in vivo and in vitro. J Steroid Biochem Mol Biol. 46, 401-13. 464 
49. Palinkas, L. et al. (2008) Developmental shift in TcR-mediated rescue of thymocytes from 465 
glucocorticoid-induced apoptosis. Immunobiology. 213, 39-50. 466 
50. Boldizsar, F. et al. (2010) Emerging pathways of non-genomic glucocorticoid (GC) signalling 467 
in T cells. Immunobiology. 215, 521-6. 468 
51. Sionov, R.V. et al. (2006) Glucocorticoid-induced apoptosis revisited: a novel role for 469 
glucocorticoid receptor translocation to the mitochondria. Cell Cycle. 5, 1017-26. 470 
52. Prenek, L. et al. (2017) The regulation of the mitochondrial apoptotic pathway by 471 
glucocorticoid receptor in collaboration with Bcl-2 family proteins in developing T cells. 472 
Apoptosis. 22, 239-253. 473 
53. Mutsaers, H.A. and Tofighi, R. (2012) Dexamethasone enhances oxidative stress-induced cell 474 
death in murine neural stem cells. Neurotox Res. 22, 127-37. 475 
54. Gosens, R. et al. (2008) Caveolae and caveolins in the respiratory system. Curr Mol Med. 8, 476 
741-53. 477 
55. Williams, T.M. and Lisanti, M.P. (2004) The caveolin proteins. Genome Biol. 5, 214. 478 
56. Matthews, L. et al. (2008) Caveolin mediates rapid glucocorticoid effects and couples 479 
glucocorticoid action to the antiproliferative program. Mol Endocrinol. 22, 1320-30. 480 
18 
 
57. Watson, C.S. et al. (2012) Estrogen- and xenoestrogen-induced ERK signaling in pituitary 481 
tumor cells involves estrogen receptor-alpha interactions with G protein-alphai and caveolin I. 482 
Steroids. 77, 424-32. 483 
58. Vernocchi, S. et al. (2013) Membrane glucocorticoid receptor activation induces proteomic 484 
changes aligning with classical glucocorticoid effects. Mol Cell Proteomics. 12, 1764-79. 485 
59. Spies, C.M. et al. (2006) Membrane glucocorticoid receptors are down regulated by 486 
glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent 487 
expression pathway. Ann Rheum Dis. 65, 1139-46. 488 
60. Czuba, L.C. et al. (2018) Post-translational modifications of transporters. Pharmacol Ther.  489 
61. Li, L. et al. (2003) Plasma membrane localization and function of the estrogen receptor alpha 490 
variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A. 100, 4807-12. 491 
62. Nicolaides, N.C. et al. (2017) The Role of S-Palmitoylation of the Human Glucocorticoid 492 
Receptor (hGR) in Mediating the Nongenomic Glucocorticoid Actions. J Mol Biochem. 6, 3-12. 493 
63. Zhang, Y. et al. (2012) Glucocorticoid acts on a putative G protein-coupled receptor to rapidly 494 
regulate the activity of NMDA receptors in hippocampal neurons. Am J Physiol Endocrinol Metab. 495 
302, E747-58. 496 
64. Tsuji, Y. et al. (2005) Differential-expression and tyrosine-phosphorylation profiles of caveolin 497 
isoforms in human T cell leukemia cell lines. Int J Mol Med. 16, 889-93. 498 
65. Tsuji, Y. et al. (2006) Quantification of caveolin isoforms using quantitative real-time RT-499 
PCR, and analysis of promoter CpG methylation of caveolin-1alpha in human T cell leukemia cell 500 
lines. Int J Mol Med. 18, 489-95. 501 
66. De Bosscher, K. et al. (2010) Classic glucocorticoids versus non-steroidal glucocorticoid 502 
receptor modulators: survival of the fittest regulator of the immune system? Brain Behav Immun. 503 
24, 1035-42. 504 
 505 
  506 
19 
 
Text boxes. 507 
 508 
Box 1: Calcium regulation, ASM tone, and asthma pathogenesis.  509 
Because airway smooth muscle (ASM) serves as the pivotal tissue regulating the bronchomotor 510 
tone, changes in the pathways regulating ASM contractile properties may play an important role 511 
in the development of abnormal lung function in asthma. Abnormal G-protein-coupled receptor 512 
(GPCR)-associated calcium homeostasis and ASM shortening may represent one of such 513 
mechanisms. Changes could occurs that at different levels of the contraction cascade including i)  514 
[Ca2+]i release from internal stores, ii) myosin light-chain kinase (MLCK) activity, iii)  myosin 515 
light chain phosphorylation (pMLC), and iv) actin-myosin crossbridge cycling leading to cell 516 
shortening. Changes in ASM shortening could also be due to changes in sensitivity of the 517 
contractile apparatus to [Ca2+]i initiated by the small GTPase, RhoA, which activates Rho kinase 518 
(ROCK) to inactivate myosin light chain phosphatase (MLCP). Decreased MLCP activity results 519 
in an increase in pMLC levels for a given level of [Ca2+]i, and thus enhancing ASM contractility. 520 
It is important to note that there are other parallel pathways where actin polymerization also 521 
mediates agonist-induced ASM shortening independently from Ca2+ and pMLC but potentially 522 
through the phosphorylation of other proteins such as vinculin. Collectively, this evidence suggests 523 
that ASM contractile function can mediate airway hyperresponsiveness in chronic airway 524 
inflammatory diseases by involving, at least partially, changes in Ca2+-regulatory pathways. 525 
 526 
Box 2. Role of NOS/NO signaling in asthma pathogenesis.  527 
Altered NO production has been implicated in the development of both acute and chronic allergen-528 
induced AHR. Production of NO occurs through the action of nitric oxide synthase (NOS), of 529 
which 3 isoforms have been identified thus far: two constitutive (c)NOS isoforms referred as 530 
neuronal (n), endothelial (e) NOS, and one inducible isoform called (i) NOS. Upon activation, 531 
cNOS isoforms produce relatively low amounts of NO, whereas iNOS can produce high and 532 
potentially damaging levels of NO. Whereas NO generated by eNOS is associated with beneficial 533 
bronchodilatory effects in allergic asthma, iNOS-derived NO is generally considered detrimental, 534 
as it has been linked to for instance epithelial damage, inflammatory cell infiltration, and mucus 535 
hypersecretion. These detrimental effects are largely due to the accumulation of Reactive Nitrogen 536 
20 
 
Species (RNS), including peroxynitrite, which are reaction products of NO and superoxide anions.  537 
Since NOS/NO signaling and RNS play key roles in chronic airway inflammatory diseases, 538 
including asthma and COPD, an acute role for GC/GR signaling and (inducible and/or endothelial) 539 
NOS activity can be envisioned. In depth studies are warranted to determine whether such 540 
functional interaction exists and whether or not targeting it would provide any therapeutic benefit 541 
for asthma.  542 
 543 
 544 
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Tables. 546 
GC effects Acute (simultaneous or within 30 min) Chronic 
(delayed) 
Genomic effects - + 
Inhibitory effects of CHX or 
Actinomycin D 
- + 
GR involvement - or + + 
Inhibitory effects of RU486 - or + + 
Type of GR involved None, membrane GR or cytosolic GR Cytosolic GR 
GR-independent mechanisms GC interaction with membrane None 
 547 
Table 1: Various criteria (either alone or in combination) used to distinguish genomic effects from 548 
non-genomic effects of glucocorticoids. 549 
 550 
 551 
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 552 
Table 2: Examples of the various cells types where GCs were reported to have non-genomic 553 
effects due their rapid onset, insensitivity to GR blockade (RU486), and protein synthesis 554 
inhibition (cycloheximide). 555 
 Cell types GCs References 
• Human bronchial epithelial cells Dexamethasone 
Triamcinolone 
Hydrocorticone 
3, 4, 10 
• Rat thymocytes Methylprednisolone 5 
• Mouse neuroblastoma cells Corticosterone 6, 14 
• Cichlid fish pituitary cells Cortisol 7 
• Mouse cortical collecting duct cells Dexamethasone  
Aldosterone 
11 
• Rat vascular smooth muscle cells Aldosterone 
Cortisol 
Dexamethasone 
12, 13, 25 
• Rat B103 neuroblastoma cells Hydrocorticosone 15 
• Guinea-pig cochlear spiral ganglion neurons Dexamethasone 16 
• Rat hippocampal neurons Corticosterone 
Dexamethasone 
BSA-conjugated cortisol 
19 
• Mouse skeletal C2C12 cells Dexamethasone 20 
• Guinea-pig tracheal tissues Budesonide 22 
• Murine airway smooth muscle cells Dexamethasone 23 
• Guinea-pig mouse model of allergic asthma Budesonide 24 
• Human vascular endothelial cells Dexamethasone 30 
23 
 
 Signaling pathways Cell types GCs References 
• 
• 
• 
PKA 
SERCA Ca2+-ATPases 
Adenylyl cyclase 
Human bronchial epithelial 
cells 
Dexamethasone 10 
• PKC Mouse cortical collecting duct 
cells 
Dexamethasone 
Aldosterone 
11 
• 
• 
IP3 accumulation 
PKC 
Rat vascular smooth muscle 
cells 
Dexamethasone 
Aldosterone 
12 
• PKA HT4 neuroblastoma cells Corticosterone 6 
• PKC Rat B103 neuroblastoma cells Corticosterone 15 
• 
• 
CaMKII 
AMPK 
Mouse skeletal myotubes Dexamethasone 20 
• PKC Tracheal smooth muscle tissues Cortisol 21 
• Rho kinase 
Rat vascular smooth muscle 
cells 
Dexamethasone 25 
• 
ROS/RNS (NO 
synthase) 
Human breast cancer cells Cortisol 26 
• NO pathways Guinea-pig cochlear spiral 
ganglion neurons 
Human vascular endothelial 
cells 
Human umbilical endothelial 
cells 
Dexamethasone 16, 30, 33 
• ERK1/2, P38MAPK, 
JNK 
PC12 cells 
Rat vascular smooth muscle 
cells 
Dexamethasone 25, 37 
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 556 
Table 3: Examples of signaling pathways activated by GCs via nongenomic mechanisms that 557 
were acute, sensitive (or insensitive) to GR blockade (RU486), and insensitive to protein 558 
synthesis inhibition (cycloheximide). 559 
  560 
• Src tyrosine kinase Human breast 
cancer cells A549 
cells 
Cortisol 
Dexamethasone 
26, 40 
• PI3K/Akt Human vascular endothelial 
cells 
Dexamethasone 30, 33 
25 
 
Figure legends.  561 
 562 
Figure 1. Acute non-genomic effects of GCs on basal and agonist-induced Ca2+ responses. 563 
GCs have been described to differentially affect basal intracellular Ca2+ ([Ca2+]i) homeostasis. 564 
Depending on the cell type studied and GC applied, GCs can either reduce or augment basal 565 
[Ca2+]i. (A) GCs may decrease [Ca2+]i by activating AC/PKA mediated mechanisms, likely 566 
through events taking place at the cell membrane level and independent of GR stimulation, 567 
ultimately leading to SERCA activation (thapsigargin-sensitive Ca2+-ATPase). (B) Conversely, 568 
GCs can activate PLC/IP3 and PKC dependent signaling cascades resulting in enhanced basal 569 
[Ca2+]i; the involvement of GR in this process is currently unknown. (C) Agonist-induced 570 
increases in [Ca2+]i can be counteracted by GC-mediated activation of AC/PKA-induced 571 
stimulation of SERCA pumps as described in ATP stimulated cells. In contrast, a functional 572 
role for PKC was determined in the effects of GC on serotonin-induced Ca2+ responses, 573 
suggesting that the acute inhibitory mechanisms of GCs are highly agonist specific. (D) Limited 574 
studies are available on acute potentiating effects by GCs on agonist-induced Ca2+ responses; 575 
in neuronal cells it was suggested that these effects are mediated via the rapid activation of 576 
Ca2+-influx through ionotropic ATP-gated purinergic 2X receptors. Whether glucocorticoid-577 
mediated membrane receptors are involved in this pathway remains to be further investigated 578 
(mGR?). These responses rely on the presence of external Ca2+. Abbreviations: AC, adenylyl 579 
cyclase; AR, agonist receptor; IP3, inositol 1, 4, 5-triphosphate; GC, glucocorticoid; mGR, 580 
membrane glucocorticoid receptor; PKA, protein kinase A; PKC, protein kinase C; SERCA, 581 
sarco/endoplasmatic reticulum Ca2+ -ATPase. 582 
  583 
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Glossary. 584 
 585 
Muscle reactivity: The ability of the muscle to respond to contractile agonists. It is impaired 586 
during pathophysiological conditions such as asthma. 587 
Calcium mobilization: Intracellular process triggered by external stimuli (e.g. contractile 588 
agonists) where calcium is released to be engaged in different cellular functions such as increased 589 
muscle reactivity and contraction. Calcium is usually acquired from extra-cellular sources 590 
(calcium influx) or intracellular stores (e.g. endoplasmic reticulum). 591 
Genomic action: Action that modulates the expression of genes.  It involves transcriptional 592 
processes where an activated transcriptional factor translocates to the nucleus and bind gene 593 
promoters to modulate their expression. Such processes require certain time and are delayed. 594 
Glucocorticoid receptor (GR): A nuclear receptor, which acts as a receptor and a transcriptional 595 
factor.  It is primary located in the cytosol. Glucocorticoids, through their lipophilicity, diffuse 596 
across the cell membrane to bind GR in the cytosol. Such binding promotes the translocation of 597 
GR to the nuclear where it binds gene promoters to modulate their expression. As described in this 598 
article, several evidence demonstrate a membrane version of GR, not acting as a transcriptional 599 
factor, but rather as a membrane receptor modulating the acute non-genomic effects of GC. 600 
Non-genomic Action: Action that does not modulate the expression of genes. It does not involve 601 
transcriptional processes or protein synthesis.  Such action promotes rapid effects on events 602 
proximal to the cell membrane to activate certain signal transduction pathways. 603 
Side effects of GC: Due to their wide range of actions that include effects on the immune system, 604 
metabolism, skeletal muscle, bone and eyes, to name just few, GC exert in addition to its intended 605 
effect, some harmful effects especially when used in high dose and in long-term like in asthma 606 
patients. Such effects usually require the genomic actions of GR.  607 
 608 
